A Better Newspaper

## Overview A comprehensive 20-year genomic surveillance study of Shigella sonnei in Victoria, Australia (2002–2024) documents the incremental acquisition of antimicrobial resistance (AMR) driving successive genotype replacements and the rise of extensively drug-resistant (XDR) strains (bioRxiv, June 17). The findings have implications for global AMR surveillance, public health policy, and antibiotic pipeline prioritization. ## Key Findings The study combines genomic data with comprehensive epidemiological data on sexual exposure and international travel to explore population dynamics of S. sonnei and the expansion of multi-drug resistant (MDR) and extensively drug-resistant (XDR) sub-lineages (bioRxiv, June 17). In Australia, shigellosis burden is reportedly predominantly in returning travellers or in men who have sex with men (MSM) (bioRxiv, June 17). The research demonstrates that AMR acquisition in this pathogen is incremental—each resistance event creates a new competitive genotype that displaces predecessors—rather than arising through single large mutational events. ## Global AMR Context XDR Shigella has been identified as a global public health threat by the WHO and CDC. The pathogen's transmission routes (primarily fecal-oral, with sexual transmission in MSM networks) make it particularly challenging to control through behavioral interventions alone. The Australian data serves as a longitudinal window into how XDR strains emerge over decades. ## Legal, Regulatory & Commercial Implications - **Antibiotic pipeline**: XDR Shigella creates clear commercial rationale for novel antibiotic development targeting gram-negative pathogens; regulatory incentives (GAIN Act equivalents) apply - **Public health liability**: Healthcare providers and public health authorities may face liability exposure if XDR infections occur following inadequate surveillance or treatment guideline updates - **Travel medicine**: Travel health clinics and insurers will face increasing questions about prophylaxis and treatment for travelers to endemic regions - **Surveillance investment**: The 20-year dataset model represents best practice; regulatory bodies may increasingly mandate genomic surveillance as part of pathogen monitoring frameworks ## Outlook XDR Shigella will continue to generate clinical and policy concern. The Australian genomic surveillance model may inform similar longitudinal studies in other countries, and findings from this preprint are likely to influence WHO treatment guidelines and national AMR action plans.